Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

Abstract

Position statement with key recommendations about identification and monitoring of at-risk patients threatened by the abrupt withdrawal of treatment, the equitable distribution of residual imiglucerase - and access to alternative treatments including those that have completed phase III clinical trials but have not yet been licensed.

Keywords

• Gaucher disease
• Cerezyme
• Imiglucerase
• Vesivirus
• Europe
• enzyme replacement therapy
• glucocerebrosidase
• withdrawal
• deficiency
• cessation
• miglustat